February 8th 2023
Comprehensive insight into the L-MIND trial including a review of efficacy outcomes as well as discussing the implications of the data into clinical practice.
Experts discuss which factors are considered when choosing treatment options for patients with R/R DLBCL as well as reviewing the mechanism of tafasitamab.
February 1st 2023
Insightful discussion among experts into a brief overview of relapsed/refractory DLBCL (R/R DLBCL).
Expert oncologists provide a brief overview of front-line treatment options for patients diagnosed with double large b-cell lymphoma (DLBCL).